Lupin Limited (Lupin) today forged a unique collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs), a pioneer in affordable medicines, and the COPD Foundation, dedicated to enhancing the lives of COPD patients. This collaboration aims to bolster access to healthcare by expanding the availability of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, to COPD patients in the US.

Lupin's Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, is currently the only generic product available that is therapeutically equivalent to Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder), 18 mcg/capsule by Boehringer Ingelheim Pharmaceuticals, Inc.

Chronic obstructive pulmonary disease (COPD) affects over 15 million adults in the US and ranks as the fourth leading cause of death in the country. This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US.

Spiro Gavaris, President US Generics, Lupin said, "We believe there is a large unmet need for improved and affordable products for patients in the US. As a leading healthcare organization, we are committed to increasing access for patients, seeking treatment options for respiratory conditions like COPD, with our respiratory portfolio and pipeline. Our collaboration with Mark Cuban Cost Plus Drug Company and the COPD Foundation reflects our intent to provide quality treatment options for patients."

"We are excited to work with Lupin and the COPD Foundation to bring lower prescription drug prices to consumers," said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company. "Cost Plus Drugs, Lupin and the COPD Foundation all share a common goal of providing consumers the lowest possible price for their prescription medication. With Cost Plus Drugs, consumers can be confident they are getting a fair price and the convenience of medication mailed directly to their homes."

"Accessible and affordable medications are a pathway to a healthier, more empowered life for COPD patients," said Jean Wright, M.D., CEO of the COPD Foundation. "Breathing freely shouldn't come at the cost of financial strain. Having a generic option will ensure that vital treatments remain within reach, allowing patients to prioritize their health."